The first-line combination of amivantamab-vmjw plus lazertinib extended OS compared with osimertinib for patients with EGFR-mutated advanced non-small cell lung cancer, according to data from the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback